Literature DB >> 9249213

Penetration of dapsone into cerebrospinal fluid of patients with AIDS.

G Gatti1, J Hossein, M Malena, M Cruciani, M Bassetti.   

Abstract

It has been proposed that dapsone in combination with pyrimethamine could be used for prophylaxis of both Pneumocystis carinii pneumonia and encephalitis due to Toxoplasma gondii. Ten patients with AIDS undergoing lumbar puncture for diagnostic purposes were studied in order to assess the penetration of dapsone into CSF. Blood and CSF samples were obtained between 3 and 72 h following administration. Six patients had received oral dapsone for at least 1 month at the dosage regimen of 100 mg twice of three times weekly and four patients had received a single oral 100 mg dose. Dapsone concentration in CSF ranged from 0.013 to 0.296 mg/L while concentrations in plasma ranged from 0.018 to 1.231 mg/L. The CSF:plasma concentration ratio ranged from 0.21 to 2.01. The MIC of dapsone in combination with pyrimethamine against T. gondii is unknown, and further data are required to confirm whether the CSF concentrations of dapsone found in our study are sufficient to inhibit T. gondii growth in patients infected with human immunodeficiency virus (HIV). The high interpatient variability of dapsone CSF concentrations warrants further studies in selected categories of patients with HIV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249213     DOI: 10.1093/jac/40.1.113

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

2.  Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.

Authors:  Sho Sato; Kota Matsumiya; Kimio Tohyama; Yohei Kosugi
Journal:  AAPS J       Date:  2021-06-03       Impact factor: 4.009

3.  Specific Treatment Exists for SARS-CoV-2 ARDS.

Authors:  Badar Kanwar; Chul Joong Lee; Jong-Hoon Lee
Journal:  Vaccines (Basel)       Date:  2021-06-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.